Xin Lang Cai Jing·2026-01-23 01:39Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. has shown fluctuations in its financing activities and financial performance, indicating potential investment opportunities and risks [1][2]. Group 2 - As of January 22, Guangdong Wannianqing's stock price increased by 0.70%, with a trading volume of 141 million yuan. The financing buy-in amount was 10.76 million yuan, while the financing repayment was 11.04 million yuan, resulting in a net financing buy-in of -284,400 yuan [1]. - The total financing and securities balance for Guangdong Wannianqing reached 116 million yuan, accounting for 3.35% of its market capitalization, which is above the 90th percentile level over the past year [1]. - The company has not engaged in any short selling activities on January 22, with a short selling balance of 0 shares, indicating a lack of bearish sentiment in the market [1]. Group 3 - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period. The average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported an operating income of 228 million yuan, a slight decrease of 0.14% year-on-year. The net profit attributable to the parent company was -8.13 million yuan, representing a significant decline of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.6 million yuan in dividends, with 40 million yuan distributed over the past three years [2].